CardioSomaticsCardioSomatics2221-71852658-5707Eco-Vector8328910.17816/22217185.2021.3.201093Research ArticlePathogenetic aspects of cardiovascular diseases: at the reception of a patient with atrial fibrillation. Pilot study dataBalashovaNatalia V.<p>Cand. Sci. (Biol.)</p>BalashovaN77@mail.ruhttps://orcid.org/0000-0002-0548-3414GuliaLeonid D.<p>doctor</p>BalashovaN77@mail.ruBenyiaRoland M.<p>Cand. Sci. (Med.)</p>BalashovaN77@mail.ruVladimirsky Moscow Regional Research Clinical Institute281020211231661691710202117102021Copyright © 2021, Eco-Vector2021<p>A major problem in arrhythmology is supraventricular arrhythmias atrial fibrillation. Remodeling of the myocardium and the formation of fibrosis zones are the cause of cardiac arrhythmias. Violations of the extracellular framework of myocardiocytes with the formation of zones of sclerotically altered areas lead to violations of the pulse from the sinoatrial node. The inflammatory reaction, which results in fibrosis, has been repeatedly confirmed by the results of histological examination of lung vein and myocardial tissue samples in patients with rhythm disorders atrial fibrillation. The paper considers the possibility of determining in the blood of patients with atrial fibrillation a highly sensitive C-reactive protein, widely used in clinical practice, as an indicator of the activity of sluggish inflammation in the myocardium with simultaneous determination of the level of vitamin D (25-OH), known, among other things, for its anti-inflammatory effects. The data of the pilot study are presented.</p>heart rhythm disordersvitamin DC-reactive proteinнарушения ритма сердцавитамин DС-реактивный белок[Григорян С.В., Азарапетян Л.Г., Адамян К.Г. Миокардиальный фиброз и фибрилляция предсердий. Российский кардиологический журнал. 2018;23(9):71-6 [Grigoryan SV, Azarapetyan LG, Adamyan KG. Miokardialnyi fibroz i fibrilliatsiia predserdii. Rossiiskii kardiologicheskii zhurnal. 2018;23(9):71-6 (in Russian)]. DOI:10.15829/1560-4071-2018-9-71-76][Разин В.А., Гимаев Р.Х. Миокардиальный фиброз в артериальной гипертензии. Ульяновский медико-биологический журнал. 2013;3:7-14 [Razin VA, Gimaev RH. Miokardial'nyi fibroz v arterial'noi gipertenzii. Ul'ianovskii mediko-biologicheskii zhurnal. 2013;3:7-14 (in Russian)].][Röcken C, Peters B, Juenemann G, et al. Atrial Amyloidosis. An Arrhythmogenic Substrate for Persistent Atrial Fibrillation. Circulation. 2002;106:2091-7. DOI:10.1161/01.CIR.0000034511.06350.DF][Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural Abnormalities in Atrial Walls Are Associated With Presence and Persistency of Atrial Fibrillation But Not With Age. J Am Coll Cardiol. 2011;58(21):2225-32. DOI:10.1016/j.jacc.2011.05.061][Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12(4):230-43.DOI:10.1038/nrcardio.2015.2][Вельков В.В. С-белок – структура, функция, методы определения. Медицинский дайджест. Медэксперт. 2008;2:33-6 [Velkov VV. S-belok – struktura, funktsiia, metody opredeleniia. Meditsinskii daidzhest. Medekspert. 2008;2:33-6 (in Russian)].][Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-upof a large cohort from southern Germany (MONICA-Augsburg). Circulation. 2004;110:1903-8. DOI:10.1161/01.CIR.0000143377.53389.C8][Вельков В.В. С-реактивный белок и липопротеин-ассоциированная фосфолипаза А2: новые факты и новые возможности для диагностики и стратификации сердечно-сосудистых рисков. Клинико-лабораторный консилиум, Научно-практический журнал (СПб). 2009;6(31):28-33 [Velkov VV. S-reaktivnyi belok i lipoprotein-assotsiirovannaia fosfolipaza A2: novye fakty i novye vozmozhnosti dlia diagnostiki i stratifikatsii serdechno-sosudistykh riskov. Kliniko-laboratornyi konsilium, Nauchno-prakticheskii zhurnal (SPb). 2009;6(31):28-33 (in Russian)].][Kwon CH, Kang JG, Lee HJ, et al. C-reactive protein and risk of atrial fibrillation in East Asians. Europace. 2017;19(10):1643-9. DOI:10.1093/europace/euw298][Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation and products on endothelial cells. Am J Physiol Renal Physiol. 2008;294(5):1059-64. DOI:10.1152/ajprenal.00051.2008][Müller K, Haahr PM, Diamant M, et al. 1,25-dihydroxyVitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine. 1992;4(6):506-12.][Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105-12.][Kong J, Qiao G, Zhang Z, et al. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 2008;74(12):1577-81. DOI:10.1038/ki.2008.452][Turin A, Bax JJ, Doukas D, et al. Interactions Among Vitamin D, Atrial Fibrillation, and the Renin-Angiotensin-Aldosterone System. Am J Cardiol. 2018;122(5):780-4. DOI:10.1016/j.amjcard.2018.05.013][Trevisan C, Piovesan F, Lucato P, et al. Parathormone, vitamin D and the risk of atrial fibrillation in older adults: A prospective study. Nutr Metab Cardiovasc Dis. 2019;29(9):939-45. DOI:10.1016/j.numecd.2019.05.064][Thompson J, Nitiahpapand R, Bhatti P, Kourliouros A. Vitamin D deficiency and atrial fibrillation. Int J Cardiol. 2015;184:159-62. DOI:10.1016/j.ijcard.2015.02.012][Cerit L. Bermuda triangle; heart failure, atrial fibrillation, and vitamin D deficiency. J Cardiovasc Med (Hagerstown). 2017;18(2):121.DOI:10.2459/JCM.0000000000000407][Huang WL, Yang J, Yang J, et al. Vitamin D and new-onset atrial fibrillation: A meta-analysis of randomized controlled trials. Hellenic J Cardiol. 2018;59(2):72-7. DOI:10.1016/j.hjc.2017.11.006][Belen E, Aykan AC, Kalaycioglu E, et al. Low-Level Vitamin D Is Associated with Atrial Fibrillation in Patients with Chronic Heart Failure. Adv Clin Exp Med. 2016;25(1):51-7. DOI:10.17219/acem/34690][Mozos I, Marginean O. Links between Vitamin D Deficiency and Cardiovascular Diseases. Biomed Res Int. 2015;2015:109275. DOI:10.1155/2015/109275][Christakos S, Dhawan P, Verstuyf A, et al. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev. 2016;96(1):365-408. DOI:10.1152/physrev.00014.2015][Древаль А.В., Крюкова И.В., Барсуков И.А., Тевосян Л.Х. Внекостные эффекты витамина D (обзор литературы). РМЖ. 2017;1:53-6 [Dreval AV, Kryukova IV, Barsukov IA, Tevosyan LH. Vnekostnye effekty vitamina D (obzor literatury). RMZh. 2017;1:53-6 (in Russian)].][Carvalho LS, Sposito AC. Vitamin D for the prevention of cardiovascular disease: Are we ready for that? Atherosclerosis. 2015;241(2):729-40. DOI:10.1016/j.atherosclerosis.2015.06.034][Scragg R, Stewart AW, Waayer D, et al. Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study: A Randomized Clinical Trial. JAMA Cardiol. 2017;2(6):608-16. DOI:10.1001/jamacardio.2017.0175][Boursiquot BC, Larson JC, Shalash OA, et al. Vitamin D with calcium supplementation and risk of atrial fibrillation in postmenopausal women. Am Heart J. 2019;209:68-78. DOI:10.1016/j.ahj.2018.12.006]